Joshua L Gowin1, Vatsalya Vatsalya1,2, Jonathan G Westman1, Melanie L Schwandt3, Selena Bartlett4, Markus Heilig5, Reza Momenan6, Vijay A Ramchandani1. 1. Section on Human Psychopharmacology, Bethesda, Maryland. 2. University of Louisville and Robley Rex VAMC, Louisville, Kentucky. 3. Office of the Clinical Director, Bethesda, Maryland. 4. Translational Research Institute, Institute for Health and Biomedial Innovation, Queensland University of Technology, Brisbane, Queensland, Australia. 5. Center for Social and Affective Neuroscience, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 6. Clinical Neuroimaging Research Core, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland.
Abstract
BACKGROUND: Pharmacotherapies for alcohol use disorder have been shown to reduce hazardous drinking and improve overall health. The effect sizes for the effectiveness of these medications, however, are small, underscoring the need to expand the range of therapeutics and develop personalized treatment approaches. Recent studies have suggested that varenicline, an α4β2-nicotinic partial agonist widely used for smoking cessation, can help alcoholics reduce drinking, but the neurocognitive underpinnings of its effectiveness remain largely unexplored. METHODS: In this double-blind study, 32 heavy drinkers were randomized to receive varenicline (2 mg/d) or placebo. After 2 weeks of dosing, participants underwent functional MRI scans, during which they viewed images of faces with either neutral or fearful expressions at baseline and following an intravenous alcohol infusion to a target breath alcohol concentration of 80 mg%. Blood oxygen level-dependent (BOLD) response was analyzed with Analysis of Functional Neuroimaging software. Linear mixed-effects models were used to examine the effects of facial expression (fearful vs. neutral) and medication (placebo vs. varenicline) on BOLD response. The effect of medication on measures of subjective response to alcohol was also examined. RESULTS: Results indicated a significant facial expression-by-medication interaction in the left amygdala. The groups showed equivalent activation to neutral faces, but, whereas the placebo group showed increased activation to fearful faces, the varenicline group showed no change in activation. Amygdala activation to fearful faces correlated with number of drinks in the previous 90 days and Obsessive Compulsive Drinking Scale scores. There was no effect of varenicline on subjective response to alcohol. CONCLUSIONS: Our results indicate that varenicline may disrupt amygdala response to fearful faces in heavy drinkers. Further, amygdala activation correlated with alcohol consumption, suggesting that the effects of varenicline may be related to aspects of drinking behavior. These results suggest that amygdala response to fearful faces may be developed as a biomarker of the effectiveness of medications being developed for the treatment of alcohol use disorder.
RCT Entities:
BACKGROUND: Pharmacotherapies for alcohol use disorder have been shown to reduce hazardous drinking and improve overall health. The effect sizes for the effectiveness of these medications, however, are small, underscoring the need to expand the range of therapeutics and develop personalized treatment approaches. Recent studies have suggested that varenicline, an α4β2-nicotinic partial agonist widely used for smoking cessation, can help alcoholics reduce drinking, but the neurocognitive underpinnings of its effectiveness remain largely unexplored. METHODS: In this double-blind study, 32 heavy drinkers were randomized to receive varenicline (2 mg/d) or placebo. After 2 weeks of dosing, participants underwent functional MRI scans, during which they viewed images of faces with either neutral or fearful expressions at baseline and following an intravenous alcohol infusion to a target breath alcohol concentration of 80 mg%. Blood oxygen level-dependent (BOLD) response was analyzed with Analysis of Functional Neuroimaging software. Linear mixed-effects models were used to examine the effects of facial expression (fearful vs. neutral) and medication (placebo vs. varenicline) on BOLD response. The effect of medication on measures of subjective response to alcohol was also examined. RESULTS: Results indicated a significant facial expression-by-medication interaction in the left amygdala. The groups showed equivalent activation to neutral faces, but, whereas the placebo group showed increased activation to fearful faces, the varenicline group showed no change in activation. Amygdala activation to fearful faces correlated with number of drinks in the previous 90 days and Obsessive Compulsive Drinking Scale scores. There was no effect of varenicline on subjective response to alcohol. CONCLUSIONS: Our results indicate that varenicline may disrupt amygdala response to fearful faces in heavy drinkers. Further, amygdala activation correlated with alcohol consumption, suggesting that the effects of varenicline may be related to aspects of drinking behavior. These results suggest that amygdala response to fearful faces may be developed as a biomarker of the effectiveness of medications being developed for the treatment of alcohol use disorder.
Authors: Ahmad R Hariri; Alessandro Tessitore; Venkata S Mattay; Francesco Fera; Daniel R Weinberger Journal: Neuroimage Date: 2002-09 Impact factor: 6.556
Authors: Tony T Yang; Vinod Menon; Stephan Eliez; Christine Blasey; Christopher D White; Amy J Reid; Ian H Gotlib; Allan L Reiss Journal: Neuroreport Date: 2002-10-07 Impact factor: 1.837
Authors: Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill Journal: J Med Chem Date: 2005-05-19 Impact factor: 7.446
Authors: Matthew E Sloan; Joshua L Gowin; Roshni Janakiraman; Corbin D Ester; Joel Stoddard; Bethany Stangl; Vijay A Ramchandani Journal: Addict Biol Date: 2019-03-01 Impact factor: 4.093
Authors: Cindy L Ehlers; Derek N Wills; Katherine J Karriker-Jaffe; David A Gilder; Evelyn Phillips; Rebecca A Bernert Journal: Behav Sci (Basel) Date: 2020-10-07
Authors: David Nutt; Alexandra Hayes; Leon Fonville; Rayyan Zafar; Emily O C Palmer; Louise Paterson; Anne Lingford-Hughes Journal: Nutrients Date: 2021-11-04 Impact factor: 5.717
Authors: Melissa A Cyders; Martin H Plawecki; William Corbin; Andrea King; Denis M McCarthy; Vijay A Ramchandani; Jessica Weafer; Sean J O'Connor Journal: Alcohol Clin Exp Res Date: 2020-03-15 Impact factor: 3.455
Authors: William J A Eiler; Mario Dzemidzic; Christina M Soeurt; Claire R Carron; Brandon G Oberlin; Robert V Considine; Jaroslaw Harezlak; David A Kareken Journal: Neuroimage Clin Date: 2017-12-12 Impact factor: 4.881
Authors: Vatsalya Vatsalya; Maiying Kong; Luis M Marsano; Zimple Kurlawala; Kan V Chandras; Melanie L Schwandt; Vijay A Ramchandani; Craig J McClain Journal: Subst Abuse Date: 2020-09-09